Italian biotech SME specializing in liver disease research, placenta-derived cell therapies, and nanotechnology-based biosafety detection across EU health consortia.
ALTA SRLU is a Siena-based biotechnology SME specializing in preclinical and clinical research services for liver diseases, immune-related conditions, and advanced cell therapies. They provide specialized biotech R&D support within large European consortia, contributing expertise in areas like hepatocellular carcinoma mechanisms, cirrhosis treatment strategies, and placenta-derived cell therapy for orthopaedic recovery. They also work on nanotechnology-based detection methods for biological safety, particularly endotoxin contamination assessment.
Projects HEP-CAR, LIVERHOPE, and ImmunoAgeing collectively address liver cancer pathogenesis, decompensated cirrhosis treatment, and immune ageing — all interconnected liver pathology topics.
PACE and HIPGEN both focus on placenta-derived stromal cells (PLX-PAD) for muscle regeneration and hip fracture recovery, spanning Phase IIb and Phase III clinical studies.
ENDONANO and PANDORA address nano-object safety and endotoxin detection using fluorescent and plasmonic nanotechnology approaches.
GLYCOVAX trained researchers in rational design of glycoconjugate vaccines, indicating capabilities in immunology and carbohydrate chemistry.
MarPipe participation suggests involvement in marine natural product pipelines, likely contributing biotech screening or assay expertise.
ALTA SRLU's early H2020 work (2015–2017) centered on understanding disease mechanisms — immune ageing, hepatocellular carcinoma pathogenesis, and nano-object immune responses. From 2017 onward, their focus shifted decisively toward translational medicine and clinical-stage work: Phase IIb/III cell therapy trials (PACE, HIPGEN) and a therapeutic strategy for decompensated cirrhosis (LIVERHOPE). Their most recent project (ENDONANO, 2019) adds a quality control and biosafety dimension through endotoxin detection nanotechnology.
ALTA SRLU is moving from basic disease research toward clinical translation and advanced therapy medicinal products, making them increasingly relevant for partners seeking clinical trial-ready biotech collaborators.
ALTA SRLU never coordinates — they join as participants (5 projects) or third-party contributors (4 projects), consistently operating as a specialist service provider within large consortia. With 88 unique partners across 20 countries, they connect broadly rather than deeply, suggesting they offer a niche capability that diverse consortia need. Their third-party role in nearly half their projects indicates they are often brought in for specific technical contributions rather than as core consortium members.
ALTA SRLU has collaborated with 88 distinct partners across 20 countries, indicating a wide European network built through both direct participation and third-party contributions. Their Siena base and health focus suggest strong ties to Italian and broader Southern European biomedical research communities.
ALTA SRLU occupies a distinctive niche as a biotech SME that bridges preclinical research and clinical-stage development, particularly in liver diseases and cell therapy. Their dual presence in both mechanistic research (HEP-CAR, ImmunoAgeing) and late-stage clinical trials (HIPGEN Phase III) is unusual for a small company — most SMEs of this size operate at only one end of the translational spectrum. For consortium builders, they offer the flexibility of a small, specialized partner who can contribute across the research-to-clinic pipeline without the overhead of a large organization.
